generation run 2026-05-07
82 min completedmodel pipeline-v5plan not recordedrun/776f02be…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- safety_data_unverified
Reproduce
- inputs
- 41 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
23 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | Grant epidemiology DSM-5 alcohol use disorder NESARC-III prevalence | 4 | 1 | Gold standard US prevalence data |
| 2 | ClinicalTrials.gov | alcohol use disorder treatment naltrexone acamprosate | 8 | 3 | Representative AUD treatment trials |
| 3 | WebSearch | blood alcohol concentration BAC levels clinical effects chart impairment | 10 | 2 | Standard clinical reference for BAC impairment levels |
| 4 | WebSearch | history of distillation alcohol fermentation ancient mesopotamia China Egypt timeline | 10 | 2 | Historical context for alcohol article |
| 5 | PubMed | Lovinger ethanol NMDA receptor inhibition electrophysiology hippocampus 1989 | 1 | 1 | Foundational primary pharmacology paper |
| 6 | PubMed | ethanol pharmacokinetics metabolism CYP2E1 alcohol dehydrogenase human | 10 | 6 | Core pharmacokinetics literature |
| 7 | WebSearch | WHO global status report alcohol health 2018 global burden deaths | 10 | 1 | WHO authoritative source for global alcohol burden |
| 8 | PubChem | ethanol (by name and CID 702) | 1 | 1 | Verified chemical identity data |
| 9 | PubMed | Koob Volkow neurobiology alcohol addiction circuits review 2016 | 1 | 1 | Definitive neurobiology of addiction framework |
| 10 | WebSearch | alcohol ethanol legal status worldwide drinking age prohibition countries | 10 | 2 | Legal status reference data |
| 11 | PubMed | ethanol GABA-A receptor positive allosteric modulator mechanism pharmacology | 10 | 3 | Focused on primary receptor pharmacology and reinforcement mechanisms |
| 12 | PubMed | ethanol NMDA receptor antagonism mechanism alcohol neuropharmacology | 2 | 1 | Relevant NMDA mechanism in alcohol context |
| 13 | PubMed | Rehm global burden disease alcohol consumption attributable mortality | 6 | 2 | Most current and comprehensive global burden estimates |
| 14 | PubMed | alcohol liver disease hepatotoxicity acetaldehyde oxidative stress mechanism review | 4 | 4 | Essential liver toxicity and carcinogenesis literature |
| 15 | PubMed | alcohol effects sleep REM EEG polysomnography | 5 | 2 | Key alcohol-sleep interaction evidence |
| 16 | PubMed | alcohol withdrawal clinical review delirium tremens benzodiazepine treatment | 8 | 1 | AWS clinical review for withdrawal section |
| 17 | PubMed | ALDH2 deficiency Asian flushing response acetaldehyde alcohol cancer risk | 2 | 1 | Critical pharmacogenomic data on ALDH2 and cancer risk |
| 18 | PubChem + Seed Data | Ethanol chemical identity verification | 1 | 1 | Chemical identity verification against seed data |
| 19 | PubMed | alcohol cardiovascular J-curve moderate drinking coronary heart disease | 2 | 1 | Cardiovascular risk-benefit evidence |
| 20 | PubMed (PMID 27475769) | Koob Volkow neurobiology addiction neurocircuitry 2016 | 1 | 1 | Authoritative addiction neurocircuitry framework |
| 21 | PubMed (PMID 2467382) | Lovinger 1989 NMDA ethanol inhibition full text | 1 | 1 | Critical primary pharmacology landmark |
| 22 | PubMed | naltrexone acamprosate disulfiram nalmefene pharmacotherapy alcohol use disorder | 8 | 4 | Comprehensive AUD pharmacotherapy literature |
| 23 | PubMed | Koob alcohol neurobiology stress CRF negative reinforcement extended amygdala | 4 | 2 | Stress-opponent model of alcohol addiction |
91 claims by section — every cited sentence, checked against its source
pharmacology24 · 15 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
The auxiliary protein Shisa7, associated with GABA-A receptor surface trafficking, has been identified as a key molecular substrate for ethanol's discriminative-stimulus and reinforcing effects; Shisa7 knockdown in rats attenuates both.supported
Shisa7 knockdown attenuated discriminative-stimulus and reinforcing effects of ethanol, alprazolam, and pentobarbital at GABA-A receptors. j.jpet.2025.103761
Ethanol also induces neurosteroid synthesis — notably allopregnanolone — in certain brain regions, providing an indirect additional GABAergic mechanismsupported
Neurosteroid positive allosteric modulators of GABA-A receptors and their interaction with alcohol acute and chronic effects. 164_2017_82
Cross-tolerance with benzodiazepines, barbiturates, and other GABAergic depressants is well-established and reflects shared GABA-A receptor-mediated mechanisms.supported
Chronic ethanol consumption alters GABA-A receptor function producing cellular tolerance, cross-tolerance to benzodiazepines and barbiturates. pmid:15031000
The potency hierarchy for NMDA inhibition across a homologous series of alcohols was linearly correlated with their intoxicating potencysupported
Potency for inhibition linearly related to intoxicating potency. pmid:2467382
The incentive-sensitization theory distinguishes drug wanting (incentive salience, mediated by mesolimbic dopamine sensitization) from drug liking (hedonic pleasure); chronic alcohol use selectively sensitizes wanting circuits, driving compulsive intake even as hedonic response diminishes.supported
Incentive-sensitization theory of addiction. Drug wanting (incentive salience) vs drug liking (pleasure) distinction. Mesolimbic dopamine sensitization underlies compulsive drug-seeking. j.1360-0443.2001.9611038.x
The functional importance of this mechanism is demonstrated by the therapeutic efficacy of mu-opioid antagonists: naltrexone reduces craving and heavy drinking days (NNT approximately 8–12), while nalmefene (mu/delta antagonist, partial kappa agonist) shows comparable efficacy (Hedges g = −0.20 ITT, −0.33 in target population).partially supported
Naltrexone: opioid receptor antagonist with established moderate efficacy for alcohol dependence. Mechanism: blocks alcohol-stimulated opioid peptide release. pmid:20201811
The functional importance of this mechanism is demonstrated by the therapeutic efficacy of mu-opioid antagonists: naltrexone reduces craving and heavy drinking days (NNT approximately 8–12), while nalmefene (mu/delta antagonist, partial kappa agonist) shows comparable efficacy (Hedges g = −0.20 ITT, −0.33 in target population).supported
Nalmefene: mu/delta opioid antagonist, partial kappa agonist. Meta-analysis confirms efficacy reducing heavy drinking days (Hedges g=-0.20 ITT; -0.33 target population). j.euroneuro.2016.10.008
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
This first-pass effect is more pronounced in men than women, partly due to higher gastric alcohol dehydrogenase (ADH) activity in men — contributing to higher blood ethanol concentrations in women at equivalent weight-adjusted doses.supported
Variability in ethanol pharmacokinetics is related to sex, with women showing higher AUC, Cmax and metabolic rate. ADH1B and ADH1C polymorphisms affect ethanol clearance. hep.23341
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Pathway 2 — CYP2E1 (microsomal ethanol oxidizing system): An inducible pathway with higher Km (~0.5–0.8 g/L) that contributes proportionally more at elevated BAC and in heavy drinkers with enzyme induction. CYP2E1 generates reactive oxygen species (ROS) alongside acetaldehyde, contributing to oxidative stress and hepatotoxicity.supported
CYP2E1 activity also results in the production of reactive oxygen species (ROS) that promote oxidative stress. ajpgi.00027.2017
Pathway 2 — CYP2E1 (microsomal ethanol oxidizing system): An inducible pathway with higher Km (~0.5–0.8 g/L) that contributes proportionally more at elevated BAC and in heavy drinkers with enzyme induction. CYP2E1 generates reactive oxygen species (ROS) alongside acetaldehyde, contributing to oxidative stress and hepatotoxicity.supported
CYP2E1 induction by ethanol, acetaldehyde production, free radical generation, oxidative stress in alcoholic liver disease. pmid:17567472
Acetaldehyde is classified as an IARC Group 1 carcinogen; it forms DNA adducts producing G→T mutations in single-stranded DNA and is causally linked to cancers of the esophagus, oral cavity, liver, head and neck, colorectum, and female breastsupported
Acetaldehyde (IARC Group 1 carcinogen) generates G→T mutations in ssDNA via translesion synthesis by Pol-zeta. Distinct mutation signature identified in alcohol-associated cancers. gkac570
Claim in pharmacology — inconclusiveinconclusiveworking →
Approximately 540 million East Asians carry the ALDH2*2 variant allele (dominant negative), causing inefficient acetaldehyde clearance and the characteristic Asian flushing response — facial flushing, tachycardia, nausea — with markedly elevated esophageal cancer risk from alcohol consumption.supported
ALDH2 deficiency causes alcohol flushing response in East Asians (~540 million people). Those with ALDH2*2 allele have impaired acetaldehyde metabolism, higher acetaldehyde exposure per drink, and dramatically elevated esophageal cancer risk from alcohol. journal.pmed.1000050
Elimination at forensically relevant BAC follows approximately zero-order kinetics: 15–20 mg/100 mL/h in non-fasted moderate drinkers, 10–15 mg/100 mL/h in fasted subjects, and 25–35 mg/100 mL/h in heavy drinkers with CYP2E1 induction; the population range spans 10–35 mg/100 mL/hpartially supported
The physiological range of ethanol elimination rates from blood is from 10 to 35 mg/100mL/h. j.forsciint.2010.02.021
Women show higher AUC, higher Cmax, and slightly faster proportional elimination than men, independent of weight-adjusted dosesupported
women showing higher AUC, Cmax and metabolic rate. hep.23341
ADH1B rs1229984 (Arg48His) and ADH1C polymorphisms significantly modulate individual pharmacokinetic parameters.supported
ADH1B and ADH1C polymorphisms affect ethanol clearance. hep.23341
safety20 · 11 ok
Claim in safety — inconclusiveinconclusiveworking →
Pathogenic mechanisms include acetaldehyde-induced direct cytotoxicity, CYP2E1-generated reactive oxygen species and oxidative stress, lipid peroxidation products (4-hydroxynonenal) stimulating collagen synthesis, TNF-α activation of Kupffer cells, and mitochondrial damage.supported
Liver injury caused by acetaldehyde toxicity, NADH-mediated steatosis, CYP2E1-generated reactive oxygen species, oxidative stress, lipid peroxidation, collagen synthesis/fibrosis, and TNF-alpha inflammation. pmid:15670660
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
It forms DNA adducts producing characteristic G→T mutations in single-stranded DNAsupported
Acetaldehyde (IARC Group 1 carcinogen) generates G→T mutations in ssDNA via translesion synthesis by Pol-zeta. gkac570
Direct salivary acetaldehyde exposure from alcoholic beverages provides an additional carcinogenic mechanism beyond systemic metabolism.supported
Salivary acetaldehyde from microbial oxidation contributes to oral/esophageal cancer risk. 1756-9966-30-3
Claim in safety — inconclusiveinconclusiveworking →
Cancer risk per drink is substantially elevated in carriers of the ALDH2*2 allele due to higher acetaldehyde exposuresupported
Those with ALDH2*2 allele have impaired acetaldehyde metabolism, higher acetaldehyde exposure per drink, and dramatically elevated esophageal cancer risk from alcohol. journal.pmed.1000050
Claim in safety — inconclusiveinconclusiveworking →
Chronic metabolic tolerance: CYP2E1 induction by repeated ethanol exposure increases hepatic metabolism rate by 2–3× in heavy drinkers (elimination rate up to 35 mg/100 mL/h vs 15 mg/100 mL/h in non-drinkers).partially supported
The physiological range of ethanol elimination rates from blood is from 10 to 35 mg/100mL/h. j.forsciint.2010.02.021
Chronic neuroadaptive tolerance: GABA-A receptor downregulation (decreased α1 subunit, altered α4/δ expression) and NMDA receptor upregulation reduce sensitivity to ethanol's effects, requiring higher doses for equivalent intoxication. This is the most clinically significant form and drives both escalating consumption and withdrawal risk.partially supported
Chronic ethanol consumption alters GABA-A receptor function producing cellular tolerance... GABA-A receptor subunit composition changes with dependence. pmid:15031000
Chronic neuroadaptive tolerance: GABA-A receptor downregulation (decreased α1 subunit, altered α4/δ expression) and NMDA receptor upregulation reduce sensitivity to ethanol's effects, requiring higher doses for equivalent intoxication. This is the most clinically significant form and drives both escalating consumption and withdrawal risk.supported
Chronic ethanol exposure causes GABA-A receptor neuroadaptations including subunit expression changes. Sex differences in GABA-A subunit (alpha1, alpha4) changes during dependence and withdrawal. pmid:9689472
Cross-tolerance extends to benzodiazepines, barbiturates, and other GABA-A positive modulators — the pharmacological basis for using benzodiazepines to manage alcohol withdrawal.supported
cross-tolerance to benzodiazepines and barbiturates, sensitization to inverse agonists. pmid:15031000
Claim in safety — inconclusiveinconclusiveworking →
European poison center data confirm substantially worsened clinical outcomes when GHB/GBL is combined with ethanol.supported
combination with other substances including alcohol worsens CNS depression and respiratory suppression outcomes. j.toxlet.2017.05.030
Controlled human studies confirm enhanced subjective euphoria, elevated heart rate, and elevated cortisol relative to cocaine alonepartially supported
greater HR increases, euphoria. Augmented subjective euphoria from cocaine+alcohol combination. pmid:9336321
Claim in safety — not_supportednot supportedworking →
Claim in safety — inconclusiveinconclusiveworking →
ALDH2 deficiency (ALDH2*2 carriers) — markedly elevated acetaldehyde exposure and esophageal cancer risk per unit of alcohol consumed.supported
Those with ALDH2*2 allele have impaired acetaldehyde metabolism, higher acetaldehyde exposure per drink, and dramatically elevated esophageal cancer risk from alcohol. journal.pmed.1000050
Claim in safety — inconclusiveinconclusiveworking →
neuroscience12 · 8 ok
Sex differences exist in the pattern of GABA-A neuroadaptation: female rats show distinct subunit composition changes compared to males following chronic ethanol exposure, potentially contributing to sex differences in withdrawal severity and treatment response.supported
Sex differences in GABA-A subunit (alpha1, alpha4) changes during dependence and withdrawal. pmid:9689472
Claim in neuroscience — inconclusiveinconclusiveworking →
Alcohol addiction progresses through three stages: (1) binge/intoxication (reward circuit engagement), (2) withdrawal/negative affect (stress circuit recruitment via CRF, norepinephrine, dynorphin), and (3) preoccupation/anticipation (executive circuit compromise and cue-driven craving)supported
Three-stage model. Negative reinforcement driven by decreased dopamine/GABA in ventral striatum; CRF, norepinephrine, dynorphin recruitment in extended amygdala. 7854_2011_129
This dissociation between tonic depletion and phasic sensitization is the neural substrate of the wanting/liking dissociation described by incentive-sensitization theory.supported
Drug wanting (incentive salience) vs drug liking (pleasure) distinction. Mesolimbic dopamine sensitization underlies compulsive drug-seeking. j.1360-0443.2001.9611038.x
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Chronic alcohol use produces structural and functional PFC damage, reducing the capacity for top-down inhibitory control over subcortical reward and stress circuits.supported
preoccupation/anticipation (glutamate dysregulation in PFC/insula). s2215-0366(16)00104-8
This three-component model — reward circuit sensitization, stress circuit recruitment, and executive circuit compromise — forms the neurocircuitry framework for alcohol addiction described by Koob and colleagues.supported
Three stages: binge/intoxication (dopamine, opioid peptides), withdrawal/negative affect (CRF, dynorphin), preoccupation/anticipation (glutamate dysregulation in PFC/insula). s2215-0366(16)00104-8
Claim in neuroscience — inconclusiveinconclusiveworking →
GABA-A receptors undergo downregulation and subunit composition changes — decreased α1 subunit expression, increased α4 and δ subunit expression in some regions — reducing the receptor's sensitivity to both endogenous GABA and exogenous modulators including ethanol and benzodiazepinessupported
Sex differences in GABA-A subunit (alpha1, alpha4) changes during dependence and withdrawal. pmid:9689472
Second-half sleep is disrupted regardless of dose, producing characteristic early morning waking and fragmented sleep architecturesupported
All doses reduce sleep onset latency and consolidate first-half sleep; second-half sleep disrupted. acer.12006
EEG studies confirm that ethanol-induced sedation is qualitatively distinct from physiological sleep: ethanol produces dose-dependent enhancement of delta oscillations but does not replicate the full spectral signature of natural NREM sleep.supported
High-dose ethanol (4.0 g/kg) produces novel anesthetic state (DISCO-T)... promotes delta oscillations. Suppresses faster EEG frequencies. j.neuropharm.2019.107913
pharmacokinetic-detail9 · 3 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Men have significantly higher gastric ADH activity than women, producing a larger first-pass effect; this sex difference in presystemic metabolism is a major contributor to higher BAC in women at equivalent weight-adjusted oral doses.supported
women showing higher AUC, Cmax and metabolic rate. ADH1B and ADH1C polymorphisms affect ethanol clearance. hep.23341
These pharmacokinetic sex differences — reduced first-pass metabolism and reduced Vd — compound to produce substantially greater ethanol exposure in women and contribute to the faster progression of alcohol-associated liver disease observed in women.partially supported
women showing higher AUC, Cmax and metabolic rate. hep.23341
Population elimination rates:supported
The physiological range of ethanol elimination rates from blood is from 10 to 35 mg/100mL/h. j.forsciint.2010.02.021
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
clinical-evidence6 · 2 ok
Acamprosate (calcium acetylhomotaurinate, 1998 mg/day in divided doses) is a weak NMDA receptor antagonist (IC50 ~5.5 mM at hippocampal neurons) that also modulates NMDA subunit expression patterns similar to memantine and MK-801supported
Acamprosate weak NMDA antagonist (IC50 ~5.5 mM in hippocampal neurons). Upregulates NMDA subunits in cortex and hippocampus similar to memantine/MK-801. pmid:11369029
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Its therapeutic mechanism involves normalization of glutamatergic hyperexcitability during protracted abstinencesupported
acamprosate (NMDA/GABA modulator). pmid:16545872
Claim in clinical-evidence — inconclusiveinconclusiveworking →
history6 · 3 ok
Claim in history — not_supportednot supportedworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
The identification of ethanol as an NMDA receptor antagonist in 1989, the characterization of GABA-A receptor subunit specificity for ethanol's reinforcing effects, the development of the allostasis and reward-deficit model of addiction, and the regulatory approval of naltrexone, acamprosate, and disulfiram as AUD pharmacotherapies represent landmarks in the fieldsupported
NMDA-activated ion current in hippocampal neurons inhibited by ethanol over 5-50 mM range (intoxicating concentrations). pmid:2467382
The identification of ethanol as an NMDA receptor antagonist in 1989, the characterization of GABA-A receptor subunit specificity for ethanol's reinforcing effects, the development of the allostasis and reward-deficit model of addiction, and the regulatory approval of naltrexone, acamprosate, and disulfiram as AUD pharmacotherapies represent landmarks in the fieldsupported
Alpha1, alpha2, alpha3, alpha5 GABA-A receptor subtype roles in behavioral effects of ethanol in rhesus macaques. acer.14000
The identification of ethanol as an NMDA receptor antagonist in 1989, the characterization of GABA-A receptor subunit specificity for ethanol's reinforcing effects, the development of the allostasis and reward-deficit model of addiction, and the regulatory approval of naltrexone, acamprosate, and disulfiram as AUD pharmacotherapies represent landmarks in the fieldsupported
Review on drug addiction neuroscience including reward dysregulation. Key framework for understanding alcohol dependence. s0893-133x(00)00195-0
summary6 · 3 ok
Three pharmacotherapies — naltrexone, acamprosate, and disulfiram — hold regulatory approval for alcohol use disorder (AUD), and active clinical investigation continues into GLP-1 receptor agonists and gene therapy approaches targeting mesolimbic dopamine circuits.partially supported
FDA-approved: disulfiram (ALDH inhibitor causing acetaldehyde accumulation), naltrexone (opioid antagonist), acamprosate (NMDA/GABA modulator). CRF, CB1 as future targets. pmid:16545872
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
It inhibits NMDA-activated ion currents by up to 61% at 50 mM — a finding linearly correlated with intoxicating potency across a homologous series of alcoholssupported
50 mM EtOH reduced NMDA current 61%... Potency for inhibition linearly related to intoxicating potency. pmid:2467382
Claim in summary — inconclusiveinconclusiveworking →
Tolerance develops through both metabolic (CYP2E1 induction) and neuroadaptive (GABA-A downregulation, NMDA upregulation) mechanismspartially supported
Chronic ethanol consumption alters GABA-A receptor function producing cellular tolerance... GABA-A receptor subunit composition changes with dependence. pmid:15031000
receptor-pharmacology4 · 3 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
In rat models, viral-mediated knockdown of Shisa7 in the nucleus accumbens shell attenuates both ethanol discrimination and self-administration, identifying Shisa7 as a novel molecular node in the ethanol reward pathway.supported
Shisa7 knockdown attenuated discriminative-stimulus and reinforcing effects of ethanol, alprazolam, and pentobarbital at GABA-A receptors. j.jpet.2025.103761
Endogenous opioids: Ethanol stimulates release of β-endorphin and enkephalins, which activate mu-opioid receptors in reward circuits. Naltrexone (mu-opioid antagonist, NNT approximately 8–12 for reducing heavy drinking) and nalmefene (mu/delta antagonist, partial kappa agonist) demonstrate the functional importance of this pathway.partially supported
Mechanism: blocks alcohol-stimulated opioid peptide release. Naltrexone: opioid receptor antagonist with established moderate efficacy for alcohol dependence. pmid:20201811
Endogenous opioids: Ethanol stimulates release of β-endorphin and enkephalins, which activate mu-opioid receptors in reward circuits. Naltrexone (mu-opioid antagonist, NNT approximately 8–12 for reducing heavy drinking) and nalmefene (mu/delta antagonist, partial kappa agonist) demonstrate the functional importance of this pathway.supported
Nalmefene: mu/delta opioid antagonist, partial kappa agonist. Counters alcohol-induced dysregulation of MOR/endorphin and KOR/dynorphin. j.euroneuro.2016.10.008
comparative-pharmacology3 · 3 ok
The combination is classified as lethal because synergistic CNS and respiratory depression can shift rapidly from sedation to coma.supported
combination with other substances including alcohol worsens CNS depression and respiratory suppression outcomes. j.toxlet.2017.05.030
Barbiturate withdrawal, like alcohol withdrawal, can produce fatal seizures — reflecting the shared GABA-A neuroadaptive mechanism.supported
cross-tolerance to benzodiazepines and barbiturates... GABA-A receptor subunit composition changes with dependence. pmid:15031000
Ethanol and benzodiazepines share a primary mechanism (GABA-A receptor positive allosteric modulation) and exhibit bidirectional cross-tolerancesupported
cross-tolerance to benzodiazepines and barbiturates... GABA-A receptor function. pmid:15031000
chemistry1 · 0 ok
Claim in chemistry — inconclusiveinconclusiveworking →